产品
编 号：F749024
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 2101829-58-5
产品详情
生物活性：
Glenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke.
体内研究：
Glenzocimab (1-8 mg/kg; i.v.) 抑制食蟹猴中胶原诱导的血小板聚集。Animal Model:Cynomolgus monkeys
Dosage:1-8 mg/kg
Administration:I.v.
Result:Reversibly inhibited collagen-induced platelet aggregation, at 2 to 8 mg/kg doses, collagen-induced platelet aggregation measured 0.5 hour after the end of the administration was fully inhibited for all cynomolgus.
体外研究：
Glenzocimab (0-100000 ng/mL) 抑制 GPVI-Fc 与固定在微量滴定板上的胶原蛋白结合，IC50 为 1.37 μg/mL。
Glenzocimab (ACT017) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke.
体内研究：
Glenzocimab (1-8 mg/kg; i.v.) 抑制食蟹猴中胶原诱导的血小板聚集。Animal Model:Cynomolgus monkeys
Dosage:1-8 mg/kg
Administration:I.v.
Result:Reversibly inhibited collagen-induced platelet aggregation, at 2 to 8 mg/kg doses, collagen-induced platelet aggregation measured 0.5 hour after the end of the administration was fully inhibited for all cynomolgus.
体外研究：
Glenzocimab (0-100000 ng/mL) 抑制 GPVI-Fc 与固定在微量滴定板上的胶原蛋白结合，IC50 为 1.37 μg/mL。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备